So far, no pediatric doses for indinavir combined with ritonavir have been defined. This study evaluated the pharmacokinetics of 400 mg of indinavir/m 2 combined with 125 mg of ritonavir/m2 every 12 h (q12h) in 14 human immunodeficiency virus type 1-infected children. The area under the concentration-time curve from 0 to 24 h and the minimum concentration of drug in serum for indinavir were similar to those for 800 mg of indinavir-100 mg of ritonavir q12h in adults, while the maximum concentration of drug in serum was slightly decreased, with geometric mean ratios (90% confidence intervals in parentheses) of 1.1 (0.87 to 1.3), 0.96 (0.60 to 1.5), and 0.80 (0.68 to 0.94), respectively.

Additional Metadata
Persistent URL,
Journal Antimicrobial Agents and Chemotherapy
Bergshoeff, A.S, Fraaij, P.L.A, van Rossum, A.M.C, Verweel, G, Wynne, L.H, Winchell, R.J, … Burger, D.M. (2004). Pharmacokinetics of Indinavir Combined with Low-Dose Ritonavir in Human Immunodeficiency Virus Type 1-Infected Children. Antimicrobial Agents and Chemotherapy, 48(5), 1904–1907. doi:10.1128/AAC.48.5.1904-1907.2004